Poseida Therapeutics to join Russell 3000, Russell 2000 Indexes

Poseida Therapeutics announced it is set to join both the broad-market Russell 3000 and small-cap Russell 2000 Indexes at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. market opens today, according to a preliminary list of additions posted following the close of the U.S. markets on May 19, 2023. “We are pleased to be included in the Russell U.S. Indexes, which stands as a testament to the significant progress we have made across our cell and gene therapy portfolios,” said Mark Gergen, Chief Executive Officer of Poseida. “With this inclusion, we believe that the increased visibility amongst the global investment community will help us continue to build awareness among investors as we work to redefine cell and gene therapies for patients with high unmet medical need.”